TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01722266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards.
Study: NCT02391883

Intervention type: DRUG
Intervention: Clopidogrel
Study: NCT01433133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: implantation
Description: subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
Study: NCT02059577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Interventions
Description: Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
Study: NCT03292783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV1501 (ABL001)
Description: VEGF/DLL4 targeting bispecific antibody
Study: NCT04421885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference
Description: 600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test
Description: 600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test
Description: 600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
Study: NCT01580020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFB002
Description: 0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexamethasone
Description: Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
Study: NCT05958810

Intervention type: DRUG
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)

Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study: NCT01212783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy
Description: Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present-Centered Therapy
Description: Present-Centered Therapy is a supportive psychotherapy.
Study: NCT02280356

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study: NCT02524106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab
Description: PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01754090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online screening and feedback
Description: An online single session screening procedure including individualized normative feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online screening and feedback
Description: An online single session screening procedure including individualized normative feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online booklet.
Description: An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online multi session follow-up
Description: An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group).
Study: NCT02217345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: growth hormone, Genotropin (Pfizer)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
Study: NCT04058678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol/Placebo
Description: This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Without intervention
Description: Women with normal ovarian reserve will not be treated in anyway, thus, randomization will not be necessary.
Study: NCT02069834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 (intervention)
Description: Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 (control)
Description: Continuation of existing HAART at the time of randomization
Study: NCT03208933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
Study: NCT02305368

Intervention type: OTHER
Intervention: Chimio-oncogramme
Description: Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
Study: NCT03405337

Intervention type: DRUG
Intervention: FVIII products
Description: Adynovate, Eloctate, Afstyla, Kovaltry

Intervention type: DRUG
Intervention: FVIII products
Description: Adynovate, Eloctate, Afstyla, Kovaltry

Intervention type: DRUG
Intervention: Conventional FVIII replacement therapies
Description: Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha

Intervention type: DRUG
Intervention: Conventional FVIII replacement therapies
Description: Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha

Intervention type: DRUG
Intervention: Conventional FVIII replacement therapies
Description: Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
Study: NCT03447483

Intervention type: OTHER
Group type: OTHER
Intervention: Patients starting a treatment by ICI
Description: Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~* every 6 weeks for treatment regimen administered every 2 or 3 weeks~* at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks
Study: NCT03520621

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT03207360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills
Description: Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
Study: NCT04394910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Study: NCT00410215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: picosalax plus bisacodyl
Description: 10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: picosalax
Description: two sachets of picosalax taken orally the day prior to colonoscopy
Study: NCT02446912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
Study: NCT00410215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium phosphate
Description: two 45 ml bottles of sodium phosphate the day prior to colonoscopy
Study: NCT01286337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bipolar vessel sealing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Study: NCT02268045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTXM83
Description: Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mabthera
Description: Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
Study: NCT00149669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: employment-based reinforcement
Description: Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
Study: NCT02033577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastrojejunal bypass
Description: RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB
Description: RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
Study: NCT01822015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT02766088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
Study: NCT00860574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treosulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Low dose starting at 2Gy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Given IV per institutional standard practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO
Study: NCT00860574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Given IV per institutional standard practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Given IV per institutional standard practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study: NCT00673322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells
Description: One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
Study: NCT03320473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IC-8 IOL
Description: The AcuFocus IC-8 intraocular lens (IC-8 IOL) is a one-piece hydrophobic acrylic posterior chamber IOL into which a circular mask with a small 1.36 mm central aperture has been embedded. The IOL mask works by extending the depth of focus and its design is based on the KAMRA corneal inlay, which operates under the principle of small aperture optics.
Study: NCT04948255

Intervention type: OTHER
Intervention: Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress
Description: Questionnaire
Study: NCT01354262

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 600 IU daily oral supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50,000 IU supplementation bi-monthly
Study: NCT03039374

Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
Study: NCT03312582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% local metformin gel
Description: After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02639819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ɛ-Aminocaproic Acid
Description: Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
Study: NCT02446912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV administration every 4 weeks from Week 0 to Week 48
Study: NCT01357031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
Study: NCT02118701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making educational training
Study: NCT02795130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sclerotomy closure
Description: Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sclerotomy closure
Description: Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
Study: NCT00879424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol (vitamin D)
Description: 1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops.
Study: NCT00595049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
Study: NCT03719729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
Study: NCT01340365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercise
Description: Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tai Chi
Description: Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
Study: NCT02247505

Intervention type: DRUG
Group type: OTHER
Intervention: Harnal-D Cap. 0.2mg

Intervention type: DRUG
Group type: OTHER
Intervention: Harnal-D Cap. 0.2mg

Intervention type: DRUG
Group type: OTHER
Intervention: Cialis Tab. 5mg

Intervention type: DRUG
Group type: OTHER
Intervention: Cialis Tab. 5mg
Study: NCT01332877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched breakfast
Description: high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control breakfast
Description: Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
Study: NCT02105948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
Study: NCT01827202

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RAS blockade discontinuation
Description: In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RAS blockade discontinuation
Description: In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Study: NCT02270606

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study: NCT02105948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% sodium chloride solution
Study: NCT02270606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV